Delcath Systems to Present at H.C. Wainwright BioConnect Conference
Event summary
- Delcath Systems (Nasdaq: DCTH) will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York.
- The company focuses on interventional oncology, specifically treating primary and metastatic liver cancers.
- Delcath's key products include HEPZATO KIT (FDA-approved for metastatic uveal melanoma) and CHEMOSAT (approved in Europe).
- HEPZATO KIT combines a chemotherapeutic drug with a proprietary Hepatic Delivery System to administer high-dose chemotherapy to the liver.
The big picture
Delcath Systems' participation in the H.C. Wainwright BioConnect Investor Conference underscores its focus on expanding investor awareness and securing additional funding for its interventional oncology solutions. The company's proprietary products, HEPZATO KIT and CHEMOSAT, position it in a niche but growing segment of liver cancer treatments, where targeted therapies are gaining traction. The strategic anomaly here is the company's reliance on a single approved indication in the U.S., which could limit its near-term revenue growth.
What we're watching
- Regulatory Expansion
- Whether Delcath can secure additional regulatory approvals for HEPZATO KIT beyond its current indication.
- Commercial Execution
- The pace at which Delcath can expand its commercial footprint in the U.S. and Europe.
- Investor Sentiment
- How the market reacts to Delcath's strategic updates and financial performance during the conference.
Related topics